{"nctId":"NCT00649792","briefTitle":"Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial","startDateStruct":{"date":"2007-08"},"conditions":["Multiple Sclerosis"],"count":214,"armGroups":[],"interventions":[{"name":"Fampridine-SR","otherNames":["4-aminopyridine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient must have been previously enrolled in the Acorda Therapeutics MS-F204 study and received either Fampridine-SR or placebo\n* Patient with clinically defined multiple sclerosis (the diagnostic criteria based on: McDonald WI, et al. Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology. 2001; 50: 121-127)\n* Patient must be at least 18 years of age. Any patient who is now over the age of 70 must be in good overall health in the judgment of the investigator\n* Patient must be of adequate cognitive function, as judged by the Investigator\n* Patients who are women of childbearing potential must have a negative urine pregnancy test at the screening visit\n\nExclusion Criteria:\n\n* Female patients who are either pregnant or breastfeeding.\n* Women of childbearing potential who are not using a specified birth control method\n* Patients discontinued prematurely from the MS-F204 study\n* Patients with a history of seizures or with evidence of past, or possible epileptiform activity on an EEG\n* Patient with either a clinically significant abnormal ECG or laboratory values at the MS-F204 EXT screening visit\n* Patient with severe renal impairment\n* Patient with angina, uncontrolled hypertension, clinically significant cardiac arrhythmias, or any other clinically significant cardiovascular abnormality, as judged by the Investigator\n* Patient with a known allergy to pyridine-containing substances or any of the inactive ingredients of the Fampridine-SR tablet\n* Patient who has received an investigational drug (other than Fampridine-SR or placebo under MS-F204 study) within 30 days of the MS-F204EXT screening visit or a patient who is scheduled to enroll in an investigational drug trial at any time during this study\n* Patient who has a history of drug or alcohol abuse within the past year","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Timed 25-Foot Walk (T25FW)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.60","spread":"0.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.53","spread":"0.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.52","spread":"0.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.46","spread":"1.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.37","spread":"1.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.35","spread":"1.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.27","spread":"1.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.17","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":"0.56"}]}]}]},{"type":"SECONDARY","title":"Subject Global Impression (SGI)","description":"For the SGI, the potential responses to the effects of the investigational drug during the preceding week were 1=terrible, 2=unhappy, 3=mostly dissatisfied, 4=neutral/ mixed, 5=mostly satisfied, 6=pleased, and 7=delighted.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.67","spread":"1.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.70","spread":"1.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.77","spread":"1.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.04","spread":"1.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.95","spread":"1.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.97","spread":"1.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.15","spread":"1.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.94","spread":"1.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.50","spread":"0.71"}]}]}]},{"type":"SECONDARY","title":"Clinician's Global Impression (CGI)","description":"The potential responses were 1=very much improved, 2=much improved, 3=somewhat improved, 4=no change, 5=somewhat worse, 6=much worse, and 7=very much worse.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.38","spread":"0.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.27","spread":"0.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.48","spread":"0.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.42","spread":"0.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.58","spread":"1.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.66","spread":"1.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.65","spread":"1.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.96","spread":"1.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.50","spread":"0.71"}]}]}]},{"type":"SECONDARY","title":"Expanded Disability Status Scale (EDSS)","description":"The EDSS was used to grade patient disability on a scale from 0.0 (normal neurological exam) to 10.0 (death)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.64","spread":"1.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.86","spread":"1.05"}]}]}]},{"type":"PRIMARY","title":"Summary of Treatment Emergent Adverse Events (TEAE).","description":"All adverse events reported were treatment emergent. Therefore, events that had a date of onset, or worsening, on or after the start of the open-label drug and up to 14 days after the last dose (for non-serious events) or up to 30 days after the last dose (for SAEs) were summarized. Any abnormal clinically significant changes in physical examination, medical history, clinical laboratory testing, 12-lead ECG, and standard EEG testing were captured as adverse events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":39,"n":214},"commonTop":["Fall","Urinary Tract Infection","Multiple Sclerosis Relapse","Muscular Weakness","Fatique"]}}}